evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,495 questions · 1,554 findings · 140 reviews · Heart

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 272 · 17.5%GRADE not reported 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Cardiovascular mortality · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

Usual care with ivabradine showed no clear difference in mortality from cardiovascular causes ( compared with placebo, usual care, or no treatment (moderate certainty).

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Time to first hospitalisation for heart failure during · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Number of days spent in hospital due to heart failure during · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Rate of serious adverse events · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Exercise capacity · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Costs · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Quality of life · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Number of days spent in hospital due to heart failure during · patients with chronic heart failure with preserved ejection fraction

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Rate of serious adverse events · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Quality of life · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Exercise capacity · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review